Impact of lipid markers and high-sensitivity C-reactive protein on the value of the 99th percentile upper reference limit for high-sensitivity cardiac troponin I

Clinica Chimica Acta

Volumn 462, Issue , 2016, Pages 193-200

  Krintus, Magdalena ^a   Kozinski, Marek ^a   Fabiszak, Tomasz ^a   Kuligowska Prusinska, Magdalena ^a   Laskowska, Ewa ^a   Lennartz, Lieselotte ^b   Nowak Los, Lena ^a   Kubica, Jacek ^a   Sypniewska, Grazyna ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

99th percentile URL; Apolipoproteins; High sensitivity C reactive protein; High sensitivity cardiac troponin; Lipids; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN I; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; KIDNEY DISEASE; LIPID BLOOD LEVEL; MALE; MYOCARDIAL DISEASE; NORMAL HUMAN; POLAND; PRIORITY JOURNAL; QUESTIONNAIRE; REFERENCE VALUE; ADOLESCENT; BLOOD; CARDIAC MUSCLE; CHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEXUAL DEVELOPMENT; STANDARDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; REFERENCE VALUES; SEX CHARACTERISTICS; TROPONIN I; YOUNG ADULT;

EID: 84991628146     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.09.020     Document Type: Article

References (51)

1. [1] Thygesen, K., Alpert, J.S., Jaffe, A.S., et al. Third universal definition of myocardial infarction. Eur. Heart J. 33 (2012), 2551–2567.
2. [2] Apple, F.S., Collinson, P.O., Analytical characteristics of high-sensitivity cardiac troponin assays. Clin. Chem. 58 (2012), 54–61.
3. [3] Krintus, M., Kozinski, M., Boudry, P., et al. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay. Clin. Chem. Lab. Med. 52 (2014), 1657–1665.
4. [4] Mueller, C., Biomarkers and acute coronary syndromes: an update. Eur. Heart J. 35 (2014), 552–556.
5. [5] Roffi, M., Patrono, C., Collet, J.P., et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 37 (2016), 267–315.
6. [6] Shah, A.S., Anand, A., Sandoval, Y., et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet 386 (2015), 2481–2488.
7. [7] Reichlin, T., Twerenbold, R., Wildi, K., et al. Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. CMAJ 187 (2015), E243–E252.
8. [8] Jarolim, P., High sensitivity cardiac troponin assays in the clinical laboratories. Clin. Chem. Lab. Med. 53 (2015), 635–652.
9. [9] Kavsak, P.A., Allen, L.C., Apple, F.S., et al. Cardiac troponin testing in the acute care setting: ordering, reporting, and high sensitivity assays—an update from the Canadian society of clinical chemists (CSCC). Clin. Biochem. 44 (2011), 1273–1277.
10. [10] Zhelev, Z., Hyde, C., Youngman, E., et al. Diagnostic accuracy of single baseline measurement of Elecsys troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: systematic review and meta-analysis. BMJ, 350, 2015, h15.
11. [11] Krintus, M., Kozinski, M., Boudry, P., et al. Defining normality in a European multinational cohort: critical factors influencing the 99th percentile upper reference limit for high sensitivity cardiac troponin I. Int. J. Cardiol. 187 (2015), 256–263.
12. [12] Collinson, P.O., Heung, Y.M., Gaze, D., et al. Influence of population selection on the 99th percentile reference value for cardiac troponin assays. Clin. Chem. 58 (2012), 219–225.
13. [13] Koerbin, G., Abhayaratna, W.P., Potter, J.M., et al. Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. Clin. Biochem. 46 (2013), 1636–1643.
14. [14] Keller, T., Ojeda, F., Zeller, T., et al. Defining a reference population to determine the 99th percentile of a contemporary sensitive cardiac troponin I assay. Int. J. Cardiol. 167 (2013), 1423–1429.
15. [15] Franzini, M., Lorenzoni, V., Masotti, S., et al. The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: a multicenter study in Italy. Clin. Chim. Acta 438 (2015), 376–381.
16. [16] Hickman, P.E., Lindahl, B., Potter, J.M., et al. Is it time to do away with the 99th percentile for cardiac troponin in the diagnosis of acute coronary syndrome and the assessment of cardiac risk?. Clin. Chem. 60 (2014), 734–736.
17. [17] CLSI, Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. CLSI Document EP28A3c. 2010, Wayne (PA) Clinical and Laboratory Standards Institute.
18. [18] Sandoval, Y., Apple, F.S., The global need to define normality: the 99th percentile value of cardiac troponin. Clin. Chem. 60 (2014), 455–462.
19. [19] Rosenson, R.S., Brewer, H.B., Rader, D.J., Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome. Circ. Res. 114 (2014), 1880–1889.
20. [20] Sypniewska, G., Bergmann, K., Krintus, M., et al. How do apolipoproteins ApoB and ApoAI perform in patients with acute coronary syndromes. J. Med. Biochem. 30 (2011), 237–243.
21. [21] Krintus, M., Kozinski, M., Kubica, J., Sypniewska, G., Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit. Rev. Clin. Lab. Sci. 51 (2014), 263–279.
22. [22] Krintus, M., Kozinski, M., Stefanska, A., et al. Value of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile. Mediat. Inflamm., 2012, 2012, 419804.
23. [23] Budzyński, J., Koziński, M., Kłopocka, M., Kubica, J.M., Kubica, J., Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. Clin. Res. Cardiol. 103 (2014), 855–886.
24. [24] McMurray, J.J., Adamopoulos, S., Anker, S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur. Heart J. 33 (2012), 1787–1847.
25. [25] The International Expert Committee, International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32 (2009), 1327–1334.
26. [26] Perk, J., De Backer, G., Gohlke, H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur. Heart J. 33 (2012), 1635–1701.
27. [27] Reiner, Z., Catapano, A.L., De Backer, G., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32 (2011), 1769–1818.
28. [28] Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359 (2008), 2195–2207.
29. [29] Walldius, G., Jungner, I., The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J. Intern. Med. 259 (2006), 493–519.
30. [30] Randox Laboratories Ltd LDL-EX “SEIKEN” (sLDL), General Insert. 2015, 562616.
31. [31] Abbott ARCHITECT STAT High Sensitive Troponin-I, Package Insert. 2013 (G1-0139/R02).
32. [32] Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150 (2009), 604–612.
33. [33] Reed, A.H., Henry, R.J., Mason, W.B., Influence of statistical method used on the resulting estimate of normal range. Clin. Chem. 17 (1971), 275–284.
34. [34] Yusuf, S., Hawken, S., Ounpuu, S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 364 (2004), 937–952.
35. [35] McQueen, M.J., Hawken, S., Wang, X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case control study. Lancet 372 (2008), 224–233.
36. [36] Walldius, G., Jungner, I., Holme, I., Aastveit, A.H., Kolar, W., Steiner, E., High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001), 2026–2033.
37. [37] Di Angelantonio, E., Gao, P., Pennells, L., et al. Lipid-related markers and cardiovascular disease prediction. JAMA 307 (2012), 2499–2506.
38. [38] Lippi, G., Lo Cascio, C., Brocco, G., et al. High-density lipoprotein cholesterol values independently and inversely predict cardiac troponin T and I concentration. Ann. Transl. Med., 4, 2016, 188.
39. [39] Nayak, S.B., Pinto Pereira, L.M., Boodoo, S., et al. Association of troponin T and altered lipid profile in patients admitted with acute myocardial infarction. Arch. Physiol. Biochem. 116 (2010), 21–27.
40. [40] Kumar, A., Sathian, B., Correlation between lipid profile and troponin I test results in patients with chest pain in Nepal. Asian Pac. J. Trop. Biomed. 3 (2013), 487–491.
41. [41] Nordestgaard, B.G., Chapman, M.J., Ray, K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31 (2010), 2844–2853.
42. [42] Kotani, K., Serban, M.C., Penson, P., Lippi, G., Banach, M., Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - some answers and still many questions. Crit. Rev. Clin. Lab. Sci., 1-9, 2016 Epub ahead of print.
43. [43] Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336 (1997), 973–979.
44. [44] Lloyd-Jones, D.M., Liu, K., Tian, L., Greenland, P., Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann. Intern. Med. 145 (2006), 35–42.
45. [45] Kaptoge, S., Di Angelantonio, E., Lowe, G., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375 (2010), 132–140.
46. [46] Kaptoge, S., Di Angelantonio, E., Pennells, L., et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N. Engl. J. Med. 367 (2012), 1310–1320.
47. [47] Wensley, F., Gao, P., Burgess, S., et al. Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ, 342, 2011, d548.
48. [48] Elliott, P., Chambers, J.C., Zhang, W., et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302 (2009), 37–48.
49. [49] Segre, C.A., Hueb, W., Garcia, R.M., et al. Troponin in diabetic patients with and without chronic coronary artery disease. BMC Cardiovasc. Disord., 15, 2015, 72.
50. [50] Mueller-Hennessen, M., Lindahl, B., Giannitsis, E., et al. Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T - sub-analysis from the TRAPID-AMI study. Int. J. Cardiol. 209 (2016), 26–33.
51. [51] Krishnaswamy, P., Lubien, E., Clopton, P., et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am. J. Med. 111 (2001), 274–279.